Please assess the completion status of the following clinical trial:

Trial Title: Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of multiple myeloma~* Has undergone melphalan-conditioned autologous peripheral blood stem cell transplant myeloma.~PATIENT CHARACTERISTICS:~* ECOG/WHO performance status 0-2~* ANC ≥ 1,000/mm³~* Platelet count ≥ 75,000/mm³~* Total bilirubin ≤ 2 times upper limit of normal (ULN)~* AST and ALT ≤ 2 times ULN~* Serum creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 90 days after completion of study treatment~* No blood, sperm, or ova donation during and for ≥ 4 weeks after completion of study treatment~* Able to obtain commercially available lenalidomide via Celegene's RevAssist® program~  * Registered in the RevAssist® program~ * Willing and able to comply with the requirements of RevAssist®~* Able to swallow capsules~* No severe or uncontrolled systemic illness~* No currently active second malignancy, other than nonmelanoma skin cancer or carcinoma in situ of the cervix~  * Patients are not considered to have a currently active malignancy if they completed therapy for the malignancy, are disease free from the malignancy for \> 5 years, and are considered by their physician to be at \< 30% risk of relapse~* No congenital long QT syndrome~* No drug or alcohol abuse within the past 12 months~* No history of allergic reactions (including erythema nodosum) attributed to compounds of similar chemical or biologic composition to lenalidomide, thalidomide, or vorinostat~* No other medical condition, including mental illness or substance abuse, deemed by the investigator(s) to likely interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the study results~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 4 weeks since prior class Ia, Ib, or Ic antiarrhythmic medication~* No prior HDAC inhibitor-like compounds (e.g., valproic acid) as anticancer therapy~* More than 30 days since prior HDAC inhibitor-like compounds for other indications (e.g., valproic acid for epilepsy)~* No prior gastrointestinal surgery or other procedure that may, in the opinion of the investigator, interfere with the absorption or swallowing of the study drugs~* No concurrent corticosteroids other than for physiologic maintenance treatment~* No concurrent radiotherapy, unless for local control of bone pain~  * Irradiated area should be as small as possible~ * Lesions within the irradiated field cannot be used for response assessment~* No concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and anticancer activity of the study drugs~* No other concurrent anticancer therapy, including chemotherapy or biologic therapy~* No other concurrent HDAC inhibitors (e.g., valproic acid)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide + Vorinostat (Type: EXPERIMENTAL): Maintenance post autologous transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).